Literature DB >> 31295363

Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders.

Melanie B Gillingham1,2, Gabriela Elizondo1, Annie Behrend1,2, Dietrich Matern3, Dale A Schoeller4, Cary O Harding1, Jonathan Q Purnell5.   

Abstract

Medical nutrition therapy for long-chain fatty acid oxidation disorders (LC-FAODs) currently emphasizes fasting avoidance, restricted dietary long-chain fatty acid intake, supplementation with medium chain triglycerides, and increased carbohydrate intake. We hypothesize that increasing dietary protein intake relative to carbohydrate intake would preserve metabolic control yet induce physical benefits including reduced hepatic lipogenesis. Therefore, we compared two dietary approaches with similar fat intake but different carbohydrate to protein ratios in participants diagnosed with LC-FAODs. Thirteen participants were enrolled and randomized into either a high-protein (PRO) or a high-carbohydrate (CHO) diet for 4 months. Baseline and 4-month assessments included body composition, ectopic lipid deposition, and resting energy expenditure. End of study assessments also included total energy expenditure, metabolic responses to oral feedings, and whole-body fatty acid oxidation capacity. At the end of the dietary intervention, both groups had similar energy expenditure, fat and glucose oxidation rates, and glucolipid responses to mixed meal and oral glucose loads. Neither dietary group experienced worsening symptoms related to their LC-FAOD. Compared to the CHO group, the PRO group exhibited increased blood levels of short-chain acylcarnitines, reduced intrahepatic lipid content, and maintained lean body mass while the CHO group lost lean mass. In patients with LC-FAODs, increasing protein intake maintained metabolic control, reduced liver fat without risk of metabolic decompensation, and helped preserve lean body mass. We propose that a modest increase in dietary protein along with fasting avoidance and fat restriction may improve body composition and energy expenditure in patients with LC-FAODs.
© 2019 SSIEM.

Entities:  

Keywords:  body composition; dietary protein; energy expenditure; fatty acid oxidation disorders; intrahepatic lipids

Mesh:

Substances:

Year:  2019        PMID: 31295363      PMCID: PMC7452215          DOI: 10.1002/jimd.12155

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  36 in total

1.  Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop.

Authors:  U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel
Journal:  J Inherit Metab Dis       Date:  2009-04-28       Impact factor: 4.982

Review 2.  Assessment of energy expenditure and fuel utilization in man.

Authors:  E Jéquier; K Acheson; Y Schutz
Journal:  Annu Rev Nutr       Date:  1987       Impact factor: 11.848

3.  Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.

Authors:  Melanie B Gillingham; Jonathan Q Purnell; Julia Jordan; Diane Stadler; Andrea M Haqq; Cary O Harding
Journal:  Mol Genet Metab       Date:  2006-09-22       Impact factor: 4.797

4.  Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.

Authors:  Melanie B Gillingham; Stephen B Heitner; Julie Martin; Sarah Rose; Amy Goldstein; Areeg Hassan El-Gharbawy; Stephanie Deward; Michael R Lasarev; Jim Pollaro; James P DeLany; Luke J Burchill; Bret Goodpaster; James Shoemaker; Dietrich Matern; Cary O Harding; Jerry Vockley
Journal:  J Inherit Metab Dis       Date:  2017-09-04       Impact factor: 4.982

5.  Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: variable expressivity of maternal illness during pregnancy and unusual presentation with infantile cholestasis and hypocalcaemia.

Authors:  J A Ibdah; M J Dasouki; A W Strauss
Journal:  J Inherit Metab Dis       Date:  1999-10       Impact factor: 4.982

Review 6.  Evidence that protein requirements have been significantly underestimated.

Authors:  Rajavel Elango; Mohammad A Humayun; Ronald O Ball; Paul B Pencharz
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-01       Impact factor: 4.294

7.  Management of an LCHADD Patient During Pregnancy and High Intensity Exercise.

Authors:  D C D van Eerd; I A Brussé; V F R Adriaens; R T Mankowski; S F E Praet; M Michels; M Langeveld
Journal:  JIMD Rep       Date:  2016-06-23

8.  Use of food quotients to predict respiratory quotients for the doubly-labelled water method of measuring energy expenditure.

Authors:  A E Black; A M Prentice; W A Coward
Journal:  Hum Nutr Clin Nutr       Date:  1986-09

Review 9.  Dietary Protein and Energy Balance in Relation to Obesity and Co-morbidities.

Authors:  Mathijs Drummen; Lea Tischmann; Blandine Gatta-Cherifi; Tanja Adam; Margriet Westerterp-Plantenga
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-06       Impact factor: 5.555

10.  Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.

Authors:  E F Diekman; G Visser; J P J Schmitz; R A J Nievelstein; M de Sain-van der Velden; M Wardrop; W L Van der Pol; S M Houten; N A W van Riel; T Takken; J A L Jeneson
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

View more
  2 in total

Review 1.  Diagnosis and Clinical Management of Long-chain Fatty-acid Oxidation Disorders: A Review.

Authors:  Joshua J Baker; Barbara K Burton
Journal:  touchREV Endocrinol       Date:  2021-09-10

Review 2.  Clinical manifestations and management of fatty acid oxidation disorders.

Authors:  J Lawrence Merritt; Erin MacLeod; Agnieszka Jurecka; Bryan Hainline
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.